Raymond James & Associates’s Ligand Pharmaceuticals LGND Stock Holding History

Raymond James & Associates’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Shares Change %	Capital Flow	Portfolio Weight	Portfolio Position
2024 Q3	$213K	Buy	+2,127	New	+$213K	﹤0.01%	3583
2023 Q2	–	Sell	-3,334	Closed	-$245K	–	3839
2023 Q1	$245K	Sell	3,334 -10	-0.3%	-$736	﹤0.01%	3348
2022 Q4	$223K	Sell	3,344 -2,053	-38%	-$137K	﹤0.01%	3364
2022 Q3	$290K	Sell	5,397 -34	-0.6%	-$1.83K	﹤0.01%	3186
2022 Q2	$302K	Sell	5,431 -176	-3%	-$9.79K	﹤0.01%	3217
2022 Q1	$393K	Hold	5,607	–	–	﹤0.01%	3202
2021 Q4	$540K	Hold	5,607	–	–	﹤0.01%	3011
2021 Q3	$487K	Sell	5,607 -266	-5%	-$23.1K	﹤0.01%	3070
2021 Q2	$481K	Sell	5,873 -21,758	-79%	-$1.78M	﹤0.01%	3090
2021 Q1	$2.63M	Sell	27,631 -14,345	-34%	-$1.36M	﹤0.01%	1830
2020 Q4	$2.6M	Sell	41,976 -895	-2%	-$55.5K	﹤0.01%	1736
2020 Q3	$2.55M	Buy	42,871 +14,063	+49%	+$836K	﹤0.01%	1604
2020 Q2	$2.01M	Buy	28,808 +13,855	+93%	+$967K	﹤0.01%	1723
2020 Q1	$678K	Sell	14,953 -1,601	-10%	-$72.6K	﹤0.01%	2217
2019 Q4	$1.08M	Sell	16,554 -2,235	-12%	-$145K	﹤0.01%	2225
2019 Q3	$1.17M	Sell	18,789 -1,047	-5%	-$65K	﹤0.01%	2106
2019 Q2	$1.41M	Buy	19,836 +897	+5%	+$63.9K	﹤0.01%	2009
2019 Q1	$1.49M	Sell	18,939 -3,216	-15%	-$252K	﹤0.01%	1962
2018 Q4	$1.88M	Sell	22,155 -5,468	-20%	-$463K	﹤0.01%	1700
2018 Q3	$4.73M	Buy	27,623 +1,582	+6%	+$271K	0.01%	1239
2018 Q2	$3.37M	Buy	26,041 +508	+2%	+$65.6K	0.01%	1423
2018 Q1	$2.63M	Buy	25,533 +10,351	+68%	+$1.07M	﹤0.01%	1530
2017 Q4	$1.3M	Buy	15,182 +1,153	+8%	+$98.5K	﹤0.01%	1977
2017 Q3	$1.19M	Buy	14,029 +141	+1%	+$12K	﹤0.01%	1989
2017 Q2	$1.05M	Buy	13,888 +357	+3%	+$27K	﹤0.01%	1994
2017 Q1	$893K	Buy	13,531 +617	+5%	+$40.7K	﹤0.01%	2037
2016 Q4	$819K	Buy	12,914 +2,818	+28%	+$179K	﹤0.01%	2049
2016 Q3	$643K	Sell	10,096 -7,306	-42%	-$465K	﹤0.01%	2118
2016 Q2	$1.3M	Buy	17,402 +8,957	+106%	+$667K	﹤0.01%	1591
2016 Q1	$564K	Buy	+8,445	New	+$564K	﹤0.01%	1982